New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more:Â The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
[google_news title=”” keyword=”glioblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Glioblastoma
- Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferationon May 8, 2024 at 5:45 am
Brain Cancer Canada is excited to announce the issuance of an $80,000 grant to support groundbreaking research by Dr. Sujoy Banik and his team at Lawson Health Research Institute in London, Ontario, ...
- How Long Does Glioblastoma Take To Develop? A Review By Doctorson May 7, 2024 at 2:28 pm
Expert opinion from Marcella Abunahman Pereira Specialization in Clinical Cardiology · 12 years of experience · Brazil Glioblastoma is a type of malignant tumor that affects the central nervous system ...
- Ask A Doctor: How Long Does Glioblastoma Take To Develop?on May 7, 2024 at 2:28 pm
Expert opinion from Marcella Abunahman Pereira Specialization in Clinical Cardiology · 12 years of experience · Brazil Glioblastoma is a type of malignant tumor that affects the central nervous system ...
- New mRNA cancer vaccine helps immune system fight deadly brain tumorson May 7, 2024 at 8:23 am
Researchers from the University of Florida have developed a new mRNA cancer vaccine to retrain the body's immune system to attack and potentially treat glioblastoma, a deadly form of brain cancer.
- Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogson May 7, 2024 at 2:29 am
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.
- Knocking out deadly brain cancer with a dual therapyon May 6, 2024 at 7:10 am
Glioblastoma is an often fatal form of brain cancer, with only 5% of patients surviving beyond five years. The cancer is difficult to treat and almost always becomes resistant to treatment. As a ...
- mRNA vaccine tackles deadly brain cancer in human trialon May 6, 2024 at 6:45 am
Glioblastoma is one of the most deadly cancers, with few treatment options available. Now, a small human clinical trial has demonstrated an mRNA vaccine that quickly rallies the immune system to fight ...
- Unlocking glioblastoma's immune suppression mechanismon May 3, 2024 at 9:13 pm
The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma -; a serious and often fatal brain cancer -; suppresses the immune system ...
- New immunosuppressive mechanism found in brain canceron May 3, 2024 at 11:54 am
Scientists have discovered how glioblastoma evades the immune system by inducing pro-tumor macrophages via a glucose based epigenetic modification.
- MRNA vaccine effective in treating glioblastoma brain cancer in small trialon May 2, 2024 at 9:24 am
An experimental cancer vaccine can quickly reprogram a person's immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.
via Bing News